- Home
- PCSA vs BMRA Comparison
PCSA vs BMRA Comparison
Compare PCSA & BMRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PCSA
- BMRA
- Stock Information
- Founded
- PCSA 2011
- BMRA 1971
- Country
- PCSA United States
- BMRA United States
- Employees
- PCSA N/A
- BMRA N/A
- Industry
- PCSA Biotechnology: Pharmaceutical Preparations
- BMRA Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- PCSA Health Care
- BMRA Health Care
- Exchange
- PCSA Nasdaq
- BMRA Nasdaq
- Market Cap
- PCSA 4.3M
- BMRA 4.5M
- IPO Year
- PCSA N/A
- BMRA N/A
- Fundamental
- Price
- PCSA $0.83
- BMRA $0.28
- Analyst Decision
- PCSA Strong Buy
- BMRA
- Analyst Count
- PCSA 2
- BMRA 0
- Target Price
- PCSA $5.00
- BMRA N/A
- AVG Volume (30 Days)
- PCSA 938.6K
- BMRA 2.4M
- Earning Date
- PCSA 10-30-2024
- BMRA 01-14-2025
- Dividend Yield
- PCSA N/A
- BMRA N/A
- EPS Growth
- PCSA N/A
- BMRA N/A
- EPS
- PCSA N/A
- BMRA N/A
- Revenue
- PCSA N/A
- BMRA $5,509,000.00
- Revenue This Year
- PCSA N/A
- BMRA N/A
- Revenue Next Year
- PCSA N/A
- BMRA N/A
- P/E Ratio
- PCSA N/A
- BMRA N/A
- Revenue Growth
- PCSA N/A
- BMRA 1.74
- 52 Week Low
- PCSA $0.81
- BMRA $0.24
- 52 Week High
- PCSA $9.28
- BMRA $1.35
- Technical
- Relative Strength Index (RSI)
- PCSA 34.88
- BMRA 39.48
- Support Level
- PCSA $0.81
- BMRA $0.26
- Resistance Level
- PCSA $0.99
- BMRA $0.48
- Average True Range (ATR)
- PCSA 0.13
- BMRA 0.03
- MACD
- PCSA -0.03
- BMRA -0.01
- Stochastic Oscillator
- PCSA 3.34
- BMRA 9.09
About PCSA Processa Pharmaceuticals Inc.
Processa Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on utilizing its "regulatory science" approach in the development of Next Generation Chemotherapy ("NGC") oncology drug products. The company's strategic prioritization is to advance its pipeline of NGC proprietary small molecule oncology drugs. The NGC products are new chemical entities, but the company work by changing the metabolism, distribution, and/or elimination of already FDA-approved cancer drugs or their active metabolites while maintaining the mechanism of how the drug kills cancer cells. The three NGC treatments in its pipeline are - NGC-Capecitabine (also referred to as NGC-Cap), PCS3117, also referred to as NGC-Gemcitabine (NGC-Gem), PCS11T, also referred to as NGC-Irinotecan (NGC-Iri).
About BMRA Biomerica Inc.
Biomerica Inc is engaged in the development, manufacturing, and marketing of medical diagnostic products designed for the early detection and monitoring of chronic diseases and medical conditions. The company focuses on products for gastrointestinal diseases, food intolerances, diabetes, and certain esoteric tests. It operates in one segment namely, the design, development, marketing and sales of diagnostic kits. The majority of the company's revenue is earned from the Asia, and also has its presence in Europe, North America, Middle East and South America.